Business Wire

Global Cybersecurity Forum (GCF) to Convene Global Leaders In-Person in February 2022

28.9.2021 15:47:00 EEST | Business Wire | Press release

Share

The 2022 edition of the Global Cybersecurity Forum (GCF) will be held on 1st and 2nd of February 2022 in Riyadh under the High Patronage of the Custodian of the Two Holy Mosques King Salman bin Abdulaziz Al Saud.

The GCF 2022 theme, Rethinking the Global Cyber Order , will focus on the root challenges in cybersecurity and explore how the global cyber community can seize upon the many benefits cyberspace offers to humanity. Building off the momentum from its previous forums, the GCF will continue to grow into an action-oriented global platform that integrates the global cybersecurity community. Through its annual events, continuous research, design and launch of new initiatives, and more, the GCF aims to catalyze socioeconomic change, push the knowledge boundaries on core cybersecurity topics, foster investment and build the foundations for global cooperation in cyberspace.

Interactive and dynamic discussions and sessions will engage prominent speakers and participants representing high-level policy makers, industry leaders, experts from NGOs, international organizations, and academia driving the conversation from a range of perspectives and experiences and cover a range of sub-themes that include:

  • The evolving international order in cyberspace;
  • The current and future state of cybersecurity threats;
  • Technologies of the future as solutions to threats;
  • The human dimensions of cybersecurity in the future of work;
  • Leveraging market forces and economic incentives
  • Bridging global cyber divides and strengthening human-centric cybersecurity

The GCF, hosted by the National Cybersecurity Authority (NCA), was launched in February 2020, during the Kingdom of Saudi Arabia’s G20 Presidency, as a global platform aiming to build a more resilient and better cyberspace for all. The platform emphasizes the importance of international collaboration among diverse stakeholders and nations to accomplish this goal. In line with these objectives, GCF has convened former Heads of States, industry leaders, policymakers, senior representatives from International Organizations, prominent academics and thought leaders from across the globe, and executives from the finance, health, energy, and transport sectors.

When COVID struck, the GCF hosted its first Virtual Dialogue entitled “Cyberspace: What Now, What Next?”, attracting over 250,000 individuals from more than 100 countries. The multi-disciplinary sessions highlighted a series of key themes for the global cybersecurity community, including economic incentives, the talent gap, investment, trust, cyber diplomacy, integrated awareness, and cyber conflict readiness.

The GCF team welcomes global participation in the coming event and looks forward to expanding dialogue and driving action together to create a better cyberspace for all.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alaa Al Faadhel
afaadhel@globalcybersecurityforum.com
https://globalcybersecurityforum.com/

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye